- Home
- ME vs ACRS Comparison
ME vs ACRS Comparison
Compare ME & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ME
- ACRS
- Stock Information
- Founded
- ME 2006
- ACRS 2012
- Country
- ME United States
- ACRS United States
- Employees
- ME N/A
- ACRS N/A
- Industry
- ME Precision Instruments
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- ME Health Care
- ACRS Health Care
- Exchange
- ME Nasdaq
- ACRS Nasdaq
- Market Cap
- ME 113.9M
- ACRS 132.0M
- IPO Year
- ME N/A
- ACRS 2015
- Fundamental
- Price
- ME $3.11
- ACRS $3.80
- Analyst Decision
- ME Hold
- ACRS Buy
- Analyst Count
- ME 1
- ACRS 6
- Target Price
- ME $9.40
- ACRS $7.20
- AVG Volume (30 Days)
- ME 453.1K
- ACRS 5.8M
- Earning Date
- ME 11-12-2024
- ACRS 11-06-2024
- Dividend Yield
- ME N/A
- ACRS N/A
- EPS Growth
- ME N/A
- ACRS N/A
- EPS
- ME N/A
- ACRS N/A
- Revenue
- ME $193,260,000.00
- ACRS $27,079,000.00
- Revenue This Year
- ME $21.93
- ACRS N/A
- Revenue Next Year
- ME $17.31
- ACRS N/A
- P/E Ratio
- ME N/A
- ACRS N/A
- Revenue Growth
- ME N/A
- ACRS 26.35
- 52 Week Low
- ME $2.66
- ACRS $0.77
- 52 Week High
- ME $20.40
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- ME 30.62
- ACRS 65.68
- Support Level
- ME $2.66
- ACRS $3.67
- Resistance Level
- ME $3.58
- ACRS $4.55
- Average True Range (ATR)
- ME 0.45
- ACRS 0.51
- MACD
- ME -0.08
- ACRS 0.17
- Stochastic Oscillator
- ME 16.90
- ACRS 56.37
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.